The combination of ever more personalized medicine, as well as complex adaptive study designs, means that oncology developers can now run successful clinical trials with smaller, more targeted subsets of patients. However, with the benefits, personalization and adaptive design also bring new challenges, with greater competition for patient access and increased complexity for sites. Matching the right sites to the right trials is, therefore, more important than ever for oncology trials.
Precision for Medicine is part of the Precision Medicine Group, an integrated team of experts that extends Precision for Medicine’s therapeutic development capabilities beyond approval and into launch strategies, marketing communication, and payer insights. As one company, the Precision Medicine Group helps pharmaceutical and life-sciences clients conquer product development and commercialization challenges in a rapidly evolving environment.